MP combination

chemotherapy protocol consisting of above cpds; used for the treatment of IgE plasma cell leukemia; do not confuse with MP protocol (melphalan and prednisone) nor with MP regimen (methotrexate and cisplatin)

Also Known As:

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Therapy Context: Research Results

Experts

1.	Ender, Stephan: 1 article (12/2013)
2.	Hernando, Diego: 1 article (12/2013)
3.	Hosten, Norbert: 1 article (12/2013)
4.	Kühn, Jens-Peter: 1 article (12/2013)
5.	Laqua, Rene: 1 article (12/2013)
6.	Meffert, Peter J: 1 article (12/2013)
7.	Pillich, Dirk-Thomas: 1 article (12/2013)
8.	Reeder, Scott: 1 article (12/2013)
9.	Schröder, Henry: 1 article (12/2013)
10.	Steveling, Antje: 1 article (12/2013)

Related Diseases

1.	Osteoporosis 12/01/2013 - "PDFF and R2*MP combination might improve the prediction in differentiating healthy subjects from those with osteoporosis."
2.	Neoplasms (Cancer) 03/03/2009 - "This research provided a preliminary indication that the tin-PEI-MP combination could be favorable to other bone-seeking radiopharmaceuticals since the maximum adsorption capacities are comparable while PEI-MP offers the opportunity of using the enhanced permeability and retention effect for enhanced tumor accumulation."
3.	Multiple Myeloma 05/01/2012 - "MP combination therapy (melphalan and prednisolone) was commenced, but the patient died of multiple myeloma 33 months later. "

Related Drugs and Biologics

1.	Radiopharmaceuticals
2.	Tin
3.	Prednisolone (Predate)
4.	Melphalan (Alkeran)

Related Therapies and Procedures

1.	Therapeutics